Eur J Cancer:铂类+5-氟尿嘧啶+西妥昔单抗可作为中国复发/转移性头颈鳞癌患者的新一线治疗方案!

2021-08-23 Nebula MedSci原创

顺铂/卡铂+5-氟尿嘧啶联合西妥昔单抗可作为国内复发性/转移性头颈部鳞状细胞癌患者的一种安全有效的一线治疗方案!

EXTREME方案(化疗[CT; 顺铂/卡铂和5-氟尿嘧啶])联合西妥昔单抗是复发性和/或转移性头颈部鳞状细胞癌(R/M SCCHN)患者的标准一线(1L)疗法,而且有国际指南的支持。

CHANGE-2试验是一项由中山大学肿瘤防治中心林桐榆教授主导的随机3期临床试验,评估了改进的CT方案(两种化疗药的剂量都下调了)联合西妥昔单抗对比单用CT方案作为中国R/M SCCHN患者的一线疗法的有效性和安全性。

受试患者随机接受6个疗程的CT+西妥昔单抗继以西妥昔单抗维持直到病情进展,或单用CT方案治疗。主要终点是由独立审查委员会(IRC)评估的无进展生存期(PFS)。

两组患者的无进展生存期和总生存期

总体上,共有243位患者被随机分至两组:CT+西妥昔单抗联合组 164位、CT组 79位。CT+西妥昔单抗联合组和CT组的中位PFS分别是5.5 vs 4.1个月(风险比[HR] 0.57 [95% CI 0.40-0.80]),中位总生存期(OS)分别是11.1 vs 8.9个月(HR 0.69 [95% CI 0.50-0.93])。此外,由IRC评估的联合组和CT组的客观缓解率(ORR)分别是50.0%和26.6%

两组常见的不良反应发生情况

最常见的需紧急治疗的3-4级不良反应在联合组和CT组的发生率分别是61.3%和48.7%。

综上所述,CHANGE-2试验结果显示,在改进的铂类/5-氟尿嘧啶方案中加入西妥昔单抗可明显改善R/M SCCHN患者的中位PFS、中位OS和ORR,而且未引发新的或意料之外的安全性问题,证实了CT联合西妥昔单抗可作为国内R/M SCCHN患者的一种安全有效的一线治疗方案。

原始出处:

Guo Ye,Luo Yi,Zhang Qingyuan et al. First-line treatment with chemotherapy plus cetuximab in Chinese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety results of the randomised, phase III CHANGE-2 trial.[J] .Eur J Cancer, 2021, 156: 35-45.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (13)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2191948, encodeId=04402191948d2, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62468231840, createdName=中和制药东哥, createdTime=Thu Mar 07 21:13:17 CST 2024, time=2024-03-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1905179, encodeId=4ce619051e986, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sun Jan 09 12:02:07 CST 2022, time=2022-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822435, encodeId=62a61822435ff, content=<a href='/topic/show?id=1cdd10294572' target=_blank style='color:#2F92EE;'>#鳞癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102945, encryptionId=1cdd10294572, topicName=鳞癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Apr 09 18:02:07 CST 2022, time=2022-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737724, encodeId=e0dd1e37724dc, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Fri May 06 19:02:07 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679470, encodeId=cc9616e947023, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90483, encryptionId=d2ea9048398, topicName=西妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271a27776763, createdName=chengjn, createdTime=Fri Aug 27 04:02:07 CST 2021, time=2021-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386825, encodeId=eab21386825dd, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479578, encodeId=5c1214e9578e7, content=<a href='/topic/show?id=432b139e91' target=_blank style='color:#2F92EE;'>#5-氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1397, encryptionId=432b139e91, topicName=5-氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=94cf7545055, createdName=12498761m58暂无昵称, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484689, encodeId=abb51484689eb, content=<a href='/topic/show?id=3502102944e7' target=_blank style='color:#2F92EE;'>#鳞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102944, encryptionId=3502102944e7, topicName=鳞癌)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20171006/a73877485ccdf6add82293e671bebe21.jpg, createdBy=745a7977375, createdName=1696533704_45270456, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542862, encodeId=fe751542862ce, content=<a href='/topic/show?id=64fe63923be' target=_blank style='color:#2F92EE;'>#氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63923, encryptionId=64fe63923be, topicName=氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8ca13497099, createdName=12498710m15暂无昵称, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545921, encodeId=3efc15459216e, content=<a href='/topic/show?id=e3ed44439b1' target=_blank style='color:#2F92EE;'>#头颈鳞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44439, encryptionId=e3ed44439b1, topicName=头颈鳞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7bf13828981, createdName=ms5106640509429053, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=)]
    2024-03-07 中和制药东哥 来自湖南省

    谢谢

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2191948, encodeId=04402191948d2, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62468231840, createdName=中和制药东哥, createdTime=Thu Mar 07 21:13:17 CST 2024, time=2024-03-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1905179, encodeId=4ce619051e986, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sun Jan 09 12:02:07 CST 2022, time=2022-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822435, encodeId=62a61822435ff, content=<a href='/topic/show?id=1cdd10294572' target=_blank style='color:#2F92EE;'>#鳞癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102945, encryptionId=1cdd10294572, topicName=鳞癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Apr 09 18:02:07 CST 2022, time=2022-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737724, encodeId=e0dd1e37724dc, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Fri May 06 19:02:07 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679470, encodeId=cc9616e947023, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90483, encryptionId=d2ea9048398, topicName=西妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271a27776763, createdName=chengjn, createdTime=Fri Aug 27 04:02:07 CST 2021, time=2021-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386825, encodeId=eab21386825dd, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479578, encodeId=5c1214e9578e7, content=<a href='/topic/show?id=432b139e91' target=_blank style='color:#2F92EE;'>#5-氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1397, encryptionId=432b139e91, topicName=5-氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=94cf7545055, createdName=12498761m58暂无昵称, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484689, encodeId=abb51484689eb, content=<a href='/topic/show?id=3502102944e7' target=_blank style='color:#2F92EE;'>#鳞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102944, encryptionId=3502102944e7, topicName=鳞癌)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20171006/a73877485ccdf6add82293e671bebe21.jpg, createdBy=745a7977375, createdName=1696533704_45270456, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542862, encodeId=fe751542862ce, content=<a href='/topic/show?id=64fe63923be' target=_blank style='color:#2F92EE;'>#氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63923, encryptionId=64fe63923be, topicName=氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8ca13497099, createdName=12498710m15暂无昵称, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545921, encodeId=3efc15459216e, content=<a href='/topic/show?id=e3ed44439b1' target=_blank style='color:#2F92EE;'>#头颈鳞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44439, encryptionId=e3ed44439b1, topicName=头颈鳞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7bf13828981, createdName=ms5106640509429053, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2191948, encodeId=04402191948d2, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62468231840, createdName=中和制药东哥, createdTime=Thu Mar 07 21:13:17 CST 2024, time=2024-03-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1905179, encodeId=4ce619051e986, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sun Jan 09 12:02:07 CST 2022, time=2022-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822435, encodeId=62a61822435ff, content=<a href='/topic/show?id=1cdd10294572' target=_blank style='color:#2F92EE;'>#鳞癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102945, encryptionId=1cdd10294572, topicName=鳞癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Apr 09 18:02:07 CST 2022, time=2022-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737724, encodeId=e0dd1e37724dc, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Fri May 06 19:02:07 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679470, encodeId=cc9616e947023, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90483, encryptionId=d2ea9048398, topicName=西妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271a27776763, createdName=chengjn, createdTime=Fri Aug 27 04:02:07 CST 2021, time=2021-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386825, encodeId=eab21386825dd, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479578, encodeId=5c1214e9578e7, content=<a href='/topic/show?id=432b139e91' target=_blank style='color:#2F92EE;'>#5-氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1397, encryptionId=432b139e91, topicName=5-氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=94cf7545055, createdName=12498761m58暂无昵称, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484689, encodeId=abb51484689eb, content=<a href='/topic/show?id=3502102944e7' target=_blank style='color:#2F92EE;'>#鳞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102944, encryptionId=3502102944e7, topicName=鳞癌)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20171006/a73877485ccdf6add82293e671bebe21.jpg, createdBy=745a7977375, createdName=1696533704_45270456, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542862, encodeId=fe751542862ce, content=<a href='/topic/show?id=64fe63923be' target=_blank style='color:#2F92EE;'>#氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63923, encryptionId=64fe63923be, topicName=氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8ca13497099, createdName=12498710m15暂无昵称, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545921, encodeId=3efc15459216e, content=<a href='/topic/show?id=e3ed44439b1' target=_blank style='color:#2F92EE;'>#头颈鳞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44439, encryptionId=e3ed44439b1, topicName=头颈鳞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7bf13828981, createdName=ms5106640509429053, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2191948, encodeId=04402191948d2, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62468231840, createdName=中和制药东哥, createdTime=Thu Mar 07 21:13:17 CST 2024, time=2024-03-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1905179, encodeId=4ce619051e986, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sun Jan 09 12:02:07 CST 2022, time=2022-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822435, encodeId=62a61822435ff, content=<a href='/topic/show?id=1cdd10294572' target=_blank style='color:#2F92EE;'>#鳞癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102945, encryptionId=1cdd10294572, topicName=鳞癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Apr 09 18:02:07 CST 2022, time=2022-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737724, encodeId=e0dd1e37724dc, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Fri May 06 19:02:07 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679470, encodeId=cc9616e947023, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90483, encryptionId=d2ea9048398, topicName=西妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271a27776763, createdName=chengjn, createdTime=Fri Aug 27 04:02:07 CST 2021, time=2021-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386825, encodeId=eab21386825dd, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479578, encodeId=5c1214e9578e7, content=<a href='/topic/show?id=432b139e91' target=_blank style='color:#2F92EE;'>#5-氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1397, encryptionId=432b139e91, topicName=5-氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=94cf7545055, createdName=12498761m58暂无昵称, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484689, encodeId=abb51484689eb, content=<a href='/topic/show?id=3502102944e7' target=_blank style='color:#2F92EE;'>#鳞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102944, encryptionId=3502102944e7, topicName=鳞癌)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20171006/a73877485ccdf6add82293e671bebe21.jpg, createdBy=745a7977375, createdName=1696533704_45270456, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542862, encodeId=fe751542862ce, content=<a href='/topic/show?id=64fe63923be' target=_blank style='color:#2F92EE;'>#氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63923, encryptionId=64fe63923be, topicName=氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8ca13497099, createdName=12498710m15暂无昵称, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545921, encodeId=3efc15459216e, content=<a href='/topic/show?id=e3ed44439b1' target=_blank style='color:#2F92EE;'>#头颈鳞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44439, encryptionId=e3ed44439b1, topicName=头颈鳞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7bf13828981, createdName=ms5106640509429053, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2191948, encodeId=04402191948d2, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62468231840, createdName=中和制药东哥, createdTime=Thu Mar 07 21:13:17 CST 2024, time=2024-03-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1905179, encodeId=4ce619051e986, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sun Jan 09 12:02:07 CST 2022, time=2022-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822435, encodeId=62a61822435ff, content=<a href='/topic/show?id=1cdd10294572' target=_blank style='color:#2F92EE;'>#鳞癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102945, encryptionId=1cdd10294572, topicName=鳞癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Apr 09 18:02:07 CST 2022, time=2022-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737724, encodeId=e0dd1e37724dc, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Fri May 06 19:02:07 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679470, encodeId=cc9616e947023, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90483, encryptionId=d2ea9048398, topicName=西妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271a27776763, createdName=chengjn, createdTime=Fri Aug 27 04:02:07 CST 2021, time=2021-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386825, encodeId=eab21386825dd, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479578, encodeId=5c1214e9578e7, content=<a href='/topic/show?id=432b139e91' target=_blank style='color:#2F92EE;'>#5-氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1397, encryptionId=432b139e91, topicName=5-氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=94cf7545055, createdName=12498761m58暂无昵称, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484689, encodeId=abb51484689eb, content=<a href='/topic/show?id=3502102944e7' target=_blank style='color:#2F92EE;'>#鳞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102944, encryptionId=3502102944e7, topicName=鳞癌)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20171006/a73877485ccdf6add82293e671bebe21.jpg, createdBy=745a7977375, createdName=1696533704_45270456, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542862, encodeId=fe751542862ce, content=<a href='/topic/show?id=64fe63923be' target=_blank style='color:#2F92EE;'>#氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63923, encryptionId=64fe63923be, topicName=氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8ca13497099, createdName=12498710m15暂无昵称, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545921, encodeId=3efc15459216e, content=<a href='/topic/show?id=e3ed44439b1' target=_blank style='color:#2F92EE;'>#头颈鳞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44439, encryptionId=e3ed44439b1, topicName=头颈鳞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7bf13828981, createdName=ms5106640509429053, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=)]
    2021-08-27 chengjn
  6. [GetPortalCommentsPageByObjectIdResponse(id=2191948, encodeId=04402191948d2, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62468231840, createdName=中和制药东哥, createdTime=Thu Mar 07 21:13:17 CST 2024, time=2024-03-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1905179, encodeId=4ce619051e986, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sun Jan 09 12:02:07 CST 2022, time=2022-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822435, encodeId=62a61822435ff, content=<a href='/topic/show?id=1cdd10294572' target=_blank style='color:#2F92EE;'>#鳞癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102945, encryptionId=1cdd10294572, topicName=鳞癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Apr 09 18:02:07 CST 2022, time=2022-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737724, encodeId=e0dd1e37724dc, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Fri May 06 19:02:07 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679470, encodeId=cc9616e947023, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90483, encryptionId=d2ea9048398, topicName=西妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271a27776763, createdName=chengjn, createdTime=Fri Aug 27 04:02:07 CST 2021, time=2021-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386825, encodeId=eab21386825dd, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479578, encodeId=5c1214e9578e7, content=<a href='/topic/show?id=432b139e91' target=_blank style='color:#2F92EE;'>#5-氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1397, encryptionId=432b139e91, topicName=5-氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=94cf7545055, createdName=12498761m58暂无昵称, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484689, encodeId=abb51484689eb, content=<a href='/topic/show?id=3502102944e7' target=_blank style='color:#2F92EE;'>#鳞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102944, encryptionId=3502102944e7, topicName=鳞癌)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20171006/a73877485ccdf6add82293e671bebe21.jpg, createdBy=745a7977375, createdName=1696533704_45270456, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542862, encodeId=fe751542862ce, content=<a href='/topic/show?id=64fe63923be' target=_blank style='color:#2F92EE;'>#氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63923, encryptionId=64fe63923be, topicName=氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8ca13497099, createdName=12498710m15暂无昵称, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545921, encodeId=3efc15459216e, content=<a href='/topic/show?id=e3ed44439b1' target=_blank style='color:#2F92EE;'>#头颈鳞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44439, encryptionId=e3ed44439b1, topicName=头颈鳞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7bf13828981, createdName=ms5106640509429053, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2191948, encodeId=04402191948d2, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62468231840, createdName=中和制药东哥, createdTime=Thu Mar 07 21:13:17 CST 2024, time=2024-03-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1905179, encodeId=4ce619051e986, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sun Jan 09 12:02:07 CST 2022, time=2022-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822435, encodeId=62a61822435ff, content=<a href='/topic/show?id=1cdd10294572' target=_blank style='color:#2F92EE;'>#鳞癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102945, encryptionId=1cdd10294572, topicName=鳞癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Apr 09 18:02:07 CST 2022, time=2022-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737724, encodeId=e0dd1e37724dc, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Fri May 06 19:02:07 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679470, encodeId=cc9616e947023, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90483, encryptionId=d2ea9048398, topicName=西妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271a27776763, createdName=chengjn, createdTime=Fri Aug 27 04:02:07 CST 2021, time=2021-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386825, encodeId=eab21386825dd, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479578, encodeId=5c1214e9578e7, content=<a href='/topic/show?id=432b139e91' target=_blank style='color:#2F92EE;'>#5-氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1397, encryptionId=432b139e91, topicName=5-氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=94cf7545055, createdName=12498761m58暂无昵称, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484689, encodeId=abb51484689eb, content=<a href='/topic/show?id=3502102944e7' target=_blank style='color:#2F92EE;'>#鳞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102944, encryptionId=3502102944e7, topicName=鳞癌)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20171006/a73877485ccdf6add82293e671bebe21.jpg, createdBy=745a7977375, createdName=1696533704_45270456, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542862, encodeId=fe751542862ce, content=<a href='/topic/show?id=64fe63923be' target=_blank style='color:#2F92EE;'>#氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63923, encryptionId=64fe63923be, topicName=氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8ca13497099, createdName=12498710m15暂无昵称, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545921, encodeId=3efc15459216e, content=<a href='/topic/show?id=e3ed44439b1' target=_blank style='color:#2F92EE;'>#头颈鳞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44439, encryptionId=e3ed44439b1, topicName=头颈鳞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7bf13828981, createdName=ms5106640509429053, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=2191948, encodeId=04402191948d2, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62468231840, createdName=中和制药东哥, createdTime=Thu Mar 07 21:13:17 CST 2024, time=2024-03-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1905179, encodeId=4ce619051e986, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sun Jan 09 12:02:07 CST 2022, time=2022-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822435, encodeId=62a61822435ff, content=<a href='/topic/show?id=1cdd10294572' target=_blank style='color:#2F92EE;'>#鳞癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102945, encryptionId=1cdd10294572, topicName=鳞癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Apr 09 18:02:07 CST 2022, time=2022-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737724, encodeId=e0dd1e37724dc, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Fri May 06 19:02:07 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679470, encodeId=cc9616e947023, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90483, encryptionId=d2ea9048398, topicName=西妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271a27776763, createdName=chengjn, createdTime=Fri Aug 27 04:02:07 CST 2021, time=2021-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386825, encodeId=eab21386825dd, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479578, encodeId=5c1214e9578e7, content=<a href='/topic/show?id=432b139e91' target=_blank style='color:#2F92EE;'>#5-氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1397, encryptionId=432b139e91, topicName=5-氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=94cf7545055, createdName=12498761m58暂无昵称, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484689, encodeId=abb51484689eb, content=<a href='/topic/show?id=3502102944e7' target=_blank style='color:#2F92EE;'>#鳞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102944, encryptionId=3502102944e7, topicName=鳞癌)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20171006/a73877485ccdf6add82293e671bebe21.jpg, createdBy=745a7977375, createdName=1696533704_45270456, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542862, encodeId=fe751542862ce, content=<a href='/topic/show?id=64fe63923be' target=_blank style='color:#2F92EE;'>#氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63923, encryptionId=64fe63923be, topicName=氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8ca13497099, createdName=12498710m15暂无昵称, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545921, encodeId=3efc15459216e, content=<a href='/topic/show?id=e3ed44439b1' target=_blank style='color:#2F92EE;'>#头颈鳞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44439, encryptionId=e3ed44439b1, topicName=头颈鳞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7bf13828981, createdName=ms5106640509429053, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=2191948, encodeId=04402191948d2, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62468231840, createdName=中和制药东哥, createdTime=Thu Mar 07 21:13:17 CST 2024, time=2024-03-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1905179, encodeId=4ce619051e986, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sun Jan 09 12:02:07 CST 2022, time=2022-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822435, encodeId=62a61822435ff, content=<a href='/topic/show?id=1cdd10294572' target=_blank style='color:#2F92EE;'>#鳞癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102945, encryptionId=1cdd10294572, topicName=鳞癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Apr 09 18:02:07 CST 2022, time=2022-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737724, encodeId=e0dd1e37724dc, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Fri May 06 19:02:07 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679470, encodeId=cc9616e947023, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90483, encryptionId=d2ea9048398, topicName=西妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271a27776763, createdName=chengjn, createdTime=Fri Aug 27 04:02:07 CST 2021, time=2021-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386825, encodeId=eab21386825dd, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479578, encodeId=5c1214e9578e7, content=<a href='/topic/show?id=432b139e91' target=_blank style='color:#2F92EE;'>#5-氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1397, encryptionId=432b139e91, topicName=5-氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=94cf7545055, createdName=12498761m58暂无昵称, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484689, encodeId=abb51484689eb, content=<a href='/topic/show?id=3502102944e7' target=_blank style='color:#2F92EE;'>#鳞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102944, encryptionId=3502102944e7, topicName=鳞癌)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20171006/a73877485ccdf6add82293e671bebe21.jpg, createdBy=745a7977375, createdName=1696533704_45270456, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542862, encodeId=fe751542862ce, content=<a href='/topic/show?id=64fe63923be' target=_blank style='color:#2F92EE;'>#氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63923, encryptionId=64fe63923be, topicName=氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8ca13497099, createdName=12498710m15暂无昵称, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545921, encodeId=3efc15459216e, content=<a href='/topic/show?id=e3ed44439b1' target=_blank style='color:#2F92EE;'>#头颈鳞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44439, encryptionId=e3ed44439b1, topicName=头颈鳞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7bf13828981, createdName=ms5106640509429053, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=2191948, encodeId=04402191948d2, content=谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=4, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62468231840, createdName=中和制药东哥, createdTime=Thu Mar 07 21:13:17 CST 2024, time=2024-03-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=1905179, encodeId=4ce619051e986, content=<a href='/topic/show?id=21f66464823' target=_blank style='color:#2F92EE;'>#治疗方案#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64648, encryptionId=21f66464823, topicName=治疗方案)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5ee4187, createdName=zhangjiqing, createdTime=Sun Jan 09 12:02:07 CST 2022, time=2022-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822435, encodeId=62a61822435ff, content=<a href='/topic/show?id=1cdd10294572' target=_blank style='color:#2F92EE;'>#鳞癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102945, encryptionId=1cdd10294572, topicName=鳞癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sat Apr 09 18:02:07 CST 2022, time=2022-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1737724, encodeId=e0dd1e37724dc, content=<a href='/topic/show?id=292f965e5b5' target=_blank style='color:#2F92EE;'>#铂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96575, encryptionId=292f965e5b5, topicName=铂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca4034296500, createdName=ms3153534357578991, createdTime=Fri May 06 19:02:07 CST 2022, time=2022-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679470, encodeId=cc9616e947023, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90483, encryptionId=d2ea9048398, topicName=西妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271a27776763, createdName=chengjn, createdTime=Fri Aug 27 04:02:07 CST 2021, time=2021-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386825, encodeId=eab21386825dd, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1479578, encodeId=5c1214e9578e7, content=<a href='/topic/show?id=432b139e91' target=_blank style='color:#2F92EE;'>#5-氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1397, encryptionId=432b139e91, topicName=5-氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=94cf7545055, createdName=12498761m58暂无昵称, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484689, encodeId=abb51484689eb, content=<a href='/topic/show?id=3502102944e7' target=_blank style='color:#2F92EE;'>#鳞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102944, encryptionId=3502102944e7, topicName=鳞癌)], attachment=null, authenticateStatus=null, createdAvatar=Bioon/avatar/20171006/a73877485ccdf6add82293e671bebe21.jpg, createdBy=745a7977375, createdName=1696533704_45270456, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542862, encodeId=fe751542862ce, content=<a href='/topic/show?id=64fe63923be' target=_blank style='color:#2F92EE;'>#氟尿嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63923, encryptionId=64fe63923be, topicName=氟尿嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a8ca13497099, createdName=12498710m15暂无昵称, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545921, encodeId=3efc15459216e, content=<a href='/topic/show?id=e3ed44439b1' target=_blank style='color:#2F92EE;'>#头颈鳞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44439, encryptionId=e3ed44439b1, topicName=头颈鳞癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e7bf13828981, createdName=ms5106640509429053, createdTime=Wed Aug 25 11:02:07 CST 2021, time=2021-08-25, status=1, ipAttribution=)]

相关资讯

Br J Cancer:berzosertib+吉西他滨±顺铂联合治疗晚期实体瘤

包括铂类药物和吉西他滨(gemcitabine)在内的化疗药物会在癌细胞中诱导潜在的致命的DNA损伤反应(DDR),这是许多癌症标准疗法的一部分。

Nat Med:Toripalimab联合吉西他滨-顺铂化疗治疗晚期鼻咽癌的3期临床研究

鼻咽癌是一种恶性肿瘤,其在全球大部分地区比较罕见,但在中国南部和东南亚流行。

Lancet oncol:卡瑞珠单抗+吉西他滨+顺铂或可成为中国复发/转移性鼻咽癌的新标准一线疗法

卡瑞珠单抗组联合吉西他滨和顺铂或可成为复发性或转移性鼻咽癌患者的新标准一线治疗方案

Br J Cancer:阿司匹林增强顺铂治疗食管鳞癌的疗效

食管癌(EC)作为中国第三大常见的癌症和第四大癌症死亡原因,据估计,每年有477,900例新发病例和375,000例死亡病例。

Eur Arch Otorhinolaryngol:顺铂化疗对内耳功能和血清prestin浓度的影响

顺铂是一种化疗烷化剂,对治疗不同的恶性肿瘤如头/颈部、肺、膀胱、宫颈、卵巢、睾丸和胃肠系统癌症非常有效。其主要副作用之一是不可逆的感音神经性听力损失(SNHL),大约62%的患者会出现这种情况。

Clin Cancer Res:局部进展期鼻咽癌患者顺铂两种不同给药方式治疗的疗效和安全性评估:随机对照临床研究

在局部进展期鼻咽癌治疗中,顺铂每3周1次(100 mg/m 2)联合放疗不劣于每周1次(40 mg/m 2)。并且每3周1次给药的严重急性毒性反应以及迟发性的听力下降较少。